Halozyme Reports Record Revenue Growth, Shares Rise Sharply
Halozyme Therapeutics (HALO) reported record second-quarter revenue of $481 million in fiscal 2026, marking a year-over-year increase of 48%. The company also posted non-GAAP diluted earnings per share of $1.90, up by nearly 43% from the previous period. These results prompted Halozyme to raise its full-year guidance for revenue, royalty income, adjusted EBITDA, and EPS. The strong performance has driven HALO shares higher, with a year-to-date gain of 59%. Institutional investors have been particularly active in buying the stock over the past year, contributing to sustained inflows that pushed share prices up by an additional 41.7% during this period. Halozyme’s long-term fundamentals remain robust, including three-year sales and EPS growth rates of +28.5% and +28%, respectively. The company has been a top-rated stock at MoneyFlows for years due to its strong financial performance and unusual buy pressure from institutional investors. HALO shares have risen 769% since the first major inflow in 2014, with continued interest signaling potential further gains.
Tickers: $HALO
Topics: Biotechnology Institutional Investment Pharmaceuticals Stock Performance